Last reviewed · How we verify
TNFa Antagonist - Adalimumab
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | TNFa Antagonist - Adalimumab |
|---|---|
| Sponsor | University of Calgary |
| Drug class | TNF-α antagonist (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF-α is a pro-inflammatory cytokine central to immune-mediated inflammatory diseases. By binding TNF-α with high affinity and specificity, adalimumab prevents its interaction with TNF receptors on immune cells and tissue, thereby suppressing the inflammatory cascade. This reduces recruitment and activation of inflammatory cells, decreasing systemic and local inflammation.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Serious infections
- Malignancy risk
Key clinical trials
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (PHASE4)
- OTIS Humira Pregnancy Registry
- Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.
- Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis (NA)
- Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (PHASE4)
- Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
- Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNFa Antagonist - Adalimumab CI brief — competitive landscape report
- TNFa Antagonist - Adalimumab updates RSS · CI watch RSS
- University of Calgary portfolio CI